Quantum convoy covers 1,000 miles for cancer

Pharmaceutical specials manufacturer raises £5,000 for charity

Ten amateur cyclists from pharmaceutical manufacturer Quantum Pharmaceutical have completed a 1,000-mile charity bike ride to raise £5,000 for Marie Curie Cancer Care.

The team signed up for the challenge after their colleague Tony Gallagher died of cancer in 2008.

Gallagher’s son, Scott, led the cycle convoy, which rode off from Land’s End in Cornwall and cycled up to 90 miles a day to cross the finishing line at John O’Groats in Caithness, Scotland a fortnight later.

‘It was a testing couple of weeks,’ said Quantum Pharmaceutical’s managing director Andy Scaife.

‘We remember Tony so fondly, and cycling a thousand miles will be nothing compared with the challenge he faced in fighting cancer. We just hope the money we raise will help other cancer sufferers as they battle with the disease.’

Quantum Pharmaceutical, based in Burnopfield, Co Durham, UK, is a pharmaceutical specials manufacturer licensed by the UK Medicines and Healthcare products Regulatory Agency (MHRA) to supply pharmacies, chemists, dispensing doctors and hospitals with bespoke medicines.

You may also like

Regulatory

Penn Pharma recalls batches of seizure drug

Following incorrect placement of screw caps on some units of Midazolam buccal liquid, which could affect drug concentration
Containment

Quantum Pharmaceutical opens aseptic manufacturing facility

Incorporates aseptic compounding and manufacturing services, including gassing isolators
Manufacturing

Quantum Pharmaceutical moves into new HQ

Opens up potential for further expansion of the UK specials manufacturer
You need to be a subscriber to read this article.
Click here to find out more.
Drug Delivery

Autoinjector platforms: optimising device selection and unlocking manufacturing efficiency for injectable pipelines

Owing to ageing populations, the increased prevalence of chronic disease and additional pressure on global healthcare systems, among other factors, the market for drug delivery devices for self-administration (autoinjectors) is growing
Ingredients

Lubrizol to showcase game-changing excipients and nutraceutical ingredients at CPHI Frankfurt

Lubrizol partners with pharmaceutical and nutraceutical companies to develop innovative solutions that improve patient outcomes and offer consumer benefits
Research & Development

Quotient Sciences and CPI to accelerate RNA drug development with joint venture

The JV will address the growing industry demand for agile solutions that bring new RNA therapeutics to patients with greater speed and confidence

OMass and Genentech to develop and commercialise therapies for inflammatory bowel disease

The collaboration leverages OMass’ Odyssion platform for the continued development of oral small molecules against a first-in-class target in inflammatory bowel disease
Subscribe now